David Schenkein

David Schenkein's Title

David Schenkein is a distinguished Board Director with a profound impact on the biotechnology and pharmaceutical sectors. Bringing over 30 years of experience as a hematologist and medical oncologist, Schenkein's expertise significantly influences the strategic direction of several companies within the life sciences industry. His roles on various boards underscore his leadership and vision in advancing medical research and patient care.

David Schenkein's Education and Expertise

David Schenkein's educational background is rooted in chemistry and medicine. He holds a B.A. in chemistry from Wesleyan University and an M.D. from the State University of New York Upstate Medical School. His extensive expertise spans therapeutics, diagnostics, medical devices, novel care delivery systems, and payer innovation. His clinical and strategic acumen have been honed through decades of experience in clinical hematology/oncology and leadership roles in top-tier biotechnology firms.

David Schenkein's Experience

David Schenkein co-leads GV’s life science investment team, leveraging his comprehensive industry knowledge to drive investment in groundbreaking medical technologies. His tenure at Genentech as Senior Vice President of Clinical Hematology/Oncology marked a period of significant advancements, including numerous successful oncology drug approvals. At Millennium Pharmaceuticals, Schenkein oversaw the clinical development and global approval of the pioneering cancer treatment Velcade®. His decade-long leadership as CEO and Board Director at Agios Pharmaceuticals further exemplifies his strategic and innovative contributions to the field.

David Schenkein's Achievements

David Schenkein's career is highlighted by several noteworthy achievements. At Millennium Pharmaceuticals, he played a crucial role in the development and worldwide approval of Velcade®, a groundbreaking therapy for multiple myeloma. During his tenure at Genentech, he was instrumental in the approval of numerous oncology drugs, solidifying his reputation as a key figure in cancer treatment advancements. As CEO of Agios Pharmaceuticals, Schenkein guided the company through significant growth and innovation, leaving a lasting impact on the industry. His current roles on the boards of Denali Therapeutics, Agios Pharmaceuticals, Treeline Biosciences, Prime Medicine, Aera Therapeutics, and Leyden Labs reflect his ongoing influence and commitment to advancing medical science.

David Schenkein's Background

David Schenkein's background is a testament to his dedication to medical science and innovation. His career began with clinical roles, transitioning into pivotal leadership positions in major biotech companies. His tenure as an adjunct Clinical Professor of Medical Oncology at Stanford University School of Medicine and current position as an Adjunct Attending Physician in Hematology at Tufts Medical Center underscore his commitment to both education and patient care. Schenkein's multifaceted career highlights his ability to bridge clinical practice with strategic leadership, driving forward advancements in the life sciences.